Safety and immunogenicity of a new trivalent inactivated split-virus influenza vaccine in healthy korean children: A randomized, double-blinded, active-controlled, Phase III study

Journal of Korean Medical Science

Volumn 26, Issue 11, 2011, Pages 1421-1427

  Kang, Jin Han ^a   Oh, Chi Eun ^b   Lee, Jina ^c   Lee, Soo Young ^d   Cha, Sung Ho ^e   Kim, Dong Soo ^f   Kim, Hyun Hee ^g   Lee, Jung Hyun ^h   Kim, Jin Tack ⁱ   Ma, Sang Hyuk ^j   Hong, Young Jin ^k   Cheong, Hee Jin ^l   Lee, Hoan Jong ^m  

^a The Catholic University of Korea   (South Korea)

^b Kosin University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Bupyeong gu   (South Korea)

^e Kyung Hee University Hospital   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ Uijeongbu St Mary's Hospital   (South Korea)

^j Changwon Fatima Hospital   (South Korea)

^k Inha University School of Medicine   (South Korea)

^l Korea University College of Medicine   (South Korea)

^m Seoul National University College of Medicine   (South Korea)

more..

Author keywords

Child; Immunogenicity; Influenza vaccines; Safety

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ARTICLE; BLOOD; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOLOGY; INFANT; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MALE; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SOUTH KOREA; VACCINATION;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; MALE; REPUBLIC OF KOREA; VACCINATION; VACCINES, INACTIVATED;

EID: 84863012488     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2011.26.11.1421     Document Type: Article

References (18)

1. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375: 1100-8.
2. Monto AS, Kioumehr F. The Tecumseh Study of Respiratory Illness. IX. Occurence of influenza in the community, 1966-1971. Am J Epidemiol 1975; 102: 553-63.
3. Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM Jr. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol 2009; 170: 679-86.
4. Macroepidemiology of Influenza Vaccination (MIV) Study Group. The macro-epidemiology of influenza vaccination in 56 countries, 1997-2003. Vaccine 2005; 23: 5133-43.
5. Song JY, Cheong HJ, Woo HJ, Wie SH, Lee JS, Chung MH, Kim YR, Jung SI, Park KH, Kim TH, Uh ST, Kim WJ. Immunogenicity and safety of trivalent inactivated influenza vaccine: a randomized, double-blind, multicenter, phase 3 clinical trial in a vaccine-limited country. J Korean Med Sci 2011; 26: 191-5.
6. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ; Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines, recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59: 1-62.
7. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007. Available at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Giuidances/Vaccines/ucm074775.htm [accessed on April 15, 2011].
8. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004; 103: 133-8.
9. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, Cho GJ, Hwang TG, Kim WJ. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010; 28: 3929-35.
10. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. 2007. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf [accessed on April 15, 2011].
11. World Health Organization. The global action plan for influenza vaccines. Available at http://www.who.int/influenza_vaccines_plan/resources/5report_gap_ag_5may11.pdf [accessed on August 05, 2011].
12. Neuzil K, Jackson L, Nelson J, Klimov A, Cox N, Bridges C, Dunn J, DeStefano F, Shay D. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 2006; 194: 1032-9.
13. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 2005; 115: 1039-47.
14. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/ 214/96). The European Agency for the Evaluation of Medicinal Products, March 1997. Available at http://www.ema.europa.eu/pdfs/human/bwp/021496en.pdf [accessed on April 15, 2011].
15. Ruben FL. Inactivated influenza virus vaccines in children. Clin Infect Dis 2004; 38: 678-88.
16. Kanra G, Marchisio P, Feiterna-Sperling C, Gaedicke G, Lazar H, Durrer P, Kürsteiner O, Herzog C, Kara A, Principi N. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004; 23: 300-6.
17. Gonzalez M, Pirez MC, Ward E, Dibarboure H, García A, Picolet H. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis Child 2000; 83: 488-91.
18. Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, Colborn DK, Kurs-Lasky M, Haralam MA, Byers CJ, Zoffel LM, Fabian IA, Bernard BS, Kerr JD. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 2003; 290: 1608-16.